Table of Contents Show
Deepinder Goyal, the entrepreneur best known for building Zomato into one of India’s most recognisable consumer brands, has turned his attention to a considerably more ambitious frontier – the human brain. His wearable technology venture, Temple, has closed a $54 million seed round backed by his personal network, early stage Zomato investors, and, strikingly, more than 30 of the company’s own employees who chose to invest their own money at par valuation, with no equity discount offered in return.
That last detail is worth pausing on. Employees investing personal capital at the same price as external backers, without any preferential terms, is not standard practice. It signals something that financial metrics rarely capture – a workforce that is not merely employed by a vision, but genuinely invested in it.
What Temple Is Building
At its core, Temple is developing a precision wearable device designed to measure cerebral blood flow continuously – a physiological metric that existing consumer hardware has never been able to track. The target market, at least initially, is elite performance athletes seeking a deeper standard of insight into how their bodies and minds function under pressure.
The science behind the product traces back to the Gravity Ageing Hypothesis, a body of research published in November 2025 through Continue Research, a longevity science initiative led by Goyal. The hypothesis proposes that gravity’s continuous downward pull gradually reduces effective blood circulation to the brain’s most metabolically demanding regions including the hypothalamus and brainstem contributing to a measurable 0.7% annual decline in cerebral blood flow beginning as early as age seven.
A Founder Betting on Himself
Goyal stepped down as Group CEO of Eternal, Zomato’s parent entity, to dedicate himself fully to these ventures, and currently serves as Vice Chairman. Temple is one part of a broader portfolio of high-risk, high conviction bets that also includes Continue Research and LAT Aerospace, a short take off and landing aircraft company he co-founded in January 2025.
Why It Matters
The wearables market is crowded and competitive. Measuring cerebral blood flow in a compact, consumer grade device – if achieved would represent a genuine category breakthrough, not an incremental improvement on what already exists. Whether Temple delivers on that promise remains to be seen. What is already evident, however, is that the people closest to the work believe it can. More than 30 employees put their own money on the line to prove it. In any venture, that is where conviction becomes credible.
